Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 766 to 780 of 1688 results for carers

  1. Corticosteroid-releasing bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitis

    In development [GID-IPG10392] Expected publication date: 05 February 2025

    Interventional procedures guidance
    In development

  2. Transperineal laser ablation for treating lower urinary tract symptoms of benign prostatic hyperplasia

    In development [GID-IPG10268] Expected publication date: 08 January 2025

    Interventional procedures guidance
    In development

  3. Setmelanotide for treating obesity caused by a rare genetic disorder in children aged 2 to 5 TS ID 11827

    Awaiting development [GID-TA11313] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida [ID5089]

    In development [GID-TA10998] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353

    In development [GID-TA11394] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]

    In development [GID-TA11402] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and living with overweight or obesity ID6441

    In development [GID-TA11544] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]

    In development [GID-TA11400] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Pembrolizumab with chemotherapy for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments [ID6363]

    In development [GID-TA11422] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Henlius (pertuzumab biosimilar) for treating HER2-positive breast cancer [TS ID 12094]

      Status ...

    Technology appraisal guidance
    Topic selection

  11. Inhaled treprostinil for treating pulmonary hypertension caused by interstitial lung disease ID6459

    In development [GID-TA11572] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Talquetamab for treating relapsed or refractory multiple myeloma after 3 treatments ID5082

    In development [GID-TA10969] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. BI 1015550 for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis [ID6446]

    Awaiting development [GID-TA11552] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer ID6452

    In development [GID-TA11557] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Zuranolone for treating severe postnatal depression ID6431

    In development [GID-TA11356] Expected publication date: TBC

    Technology appraisal guidance
    In development